reziciclideg   Click here for help

GtoPdb Ligand ID: 14626

Synonyms: compound B201 [WO2023220640]
Compound class: Synthetic organic
Comment: Reziciclideg is the INN for a cyclin-dependent kinase degrader that was included in WHO INN Proposed List 135 (July 2026). Its structure suggests that it engages the cereblon (CRBN) E3 ubiquitin ligase. The compound is proposed as an antineoplastic agent. Note that the structure here has no specified stereo and is intended to represent the racemic mixture of isomers of the compound. The chemical structure is claimed in BioTheryX patents, for action as a CDK4/6 degrader [1-2]. Reziciclideg is predicted to be the INN for BioTheryX lead CDK4/6 PROTAC BTX-9341.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 142.38
Molecular weight 745.91
XLogP 1.73
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C(C(=O)C)C(=O)N(C2CCCC2)C3=C1C=NC(=N3)NC4=CC=C(C=N4)N5CCC(CCN6CCN(CC6)C7=CC=C(C=C7)C8CCC(=O)NC8=O)CC5
Isomeric SMILES O=C1C(C(=O)C)=C(C=2C=NC(=NC2N1C3CCCC3)NC4=NC=C(C=C4)N5CCC(CC5)CCN6CCN(C7=CC=C(C=C7)C8C(=O)NC(=O)CC8)CC6)C
InChI InChI=1S/C42H51N9O4/c1-27-35-26-44-42(47-39(35)51(32-5-3-4-6-32)41(55)38(27)28(2)52)45-36-13-11-33(25-43-36)49-19-16-29(17-20-49)15-18-48-21-23-50(24-22-48)31-9-7-30(8-10-31)34-12-14-37(53)46-40(34)54/h7-11,13,25-26,29,32,34H,3-6,12,14-24H2,1-2H3,(H,46,53,54)(H,43,44,45,47)
InChI Key CSBZXBPFGOKMKW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
BTX-9341 was progressed as a clinical candidate. In addition to safety and tolerability, the initial study was designed to evaluate CDK4/6 degradatoin with or without fulvestrant in patients with breast cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06515470 Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer Phase 1 Interventional Biotheryx, Inc.